bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 5:48 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 5:48 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Zacks News
Recession is Coming! Not
by Kevin Cook
Even if Dalio is only half right, we can bank on the "melt up" and monitor the data like an interest rate hawk
Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid
by Zacks Equity Research
Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.
Bluebird Up on Buyout Speculation After Celgene/Juno Deal
by Zacks Equity Research
Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.
Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion
by Zacks Equity Research
Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.
bluebird bio (BLUE) Soars: Stock Adds 7.3% in Session
by Zacks Equity Research
bluebird bio (BLUE) was a big mover last session, as the company saw its shares rise more than 7% on the day.
Is Celgene (CELG) Looking to Take Over Juno Therapeutics?
by Zacks Equity Research
There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.
Celgene Provides 2017 Preliminary Results & 2018 View
by Zacks Equity Research
Celgene Corporation (CELG) provided preliminary results for 2017 and upbeat guidance for 2018. The company suffered a few setbacks of late and is looking to bolster its pipeline.
4 Biotech Stocks That More Than Doubled This Year
by Zacks Equity Research
We take a look at a few biotech stocks whose price has increased more than 100% in 2017.
CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More
by Zacks Equity Research
The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.
Company News For Dec 12, 2017
by Zacks Equity Research
Companies in the news are: KMG,ARGX,BPMC,BLUE
Bluebird's Shares Jump on Strong Data for CAR-T Therapy
by Zacks Equity Research
bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.
Novartis Reports Updated Results from Kymriah's JULIET Study
by Zacks Equity Research
Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.
Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
by Ryan McQueeney
Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.
Gilead Sciences to Acquire Cell Design Labs for $567 Million
by Zacks Equity Research
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
Celgene CAR-T Therapy Gets Breakthrough Therapy Designation
by Zacks Equity Research
FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.
Why Earnings Season Could Be Great for bluebird bio (BLUE)
by Zacks Equity Research
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
5 Top Performing Stocks of the Top ETF of August
by Sweta Killa
Inside the top performing ETF of August and its top stocks.
bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session
by Zacks Equity Research
bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap
by Ryan McQueeney
The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world.
Indecision Won't Kill You, But It Will Take Your Money
by Kevin Cook
The pitfalls and powers of decision-making for traders and investors could be a model for everyone else.
Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition
by Ryan McQueeney
Shares of Juno Therapeutics (JUNO) continued to soar on Tuesday. The stock has now gained nearly 40% since the announcement that fellow CAR-T cancer therapy designer Kite Pharma (KITE) is being acquired by biotech behemoth Gilead Sciences (GILD).
Novartis CAR-T Therapy Drug Recommended by FDA Panel
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously (10-0) recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel).
bluebird bio (BLUE) Looks Good: Stock Adds 8.5% in Session
by Zacks Equity Research
bluebird bio saw its shares rise almost 9% on the day on the back of the company's recently released updated results from an ongoing early-stage clinical trial in relapsed/refractory multiple myeloma..
bluebird Stock Up on Positive Interim Multiple Myeloma Data
by Zacks Equity Research
bluebird bio (BLUE) reported encouraging interim phase I data on its anti-BCMA CAR T cell candidate, bb2121, in relapsed/refractory multiple myeloma patients.
Here's Why Bluebird Bio (BLUE) is Rallying Today
by Madeleine Johnson
On Thursday, shares of Bluebird Bio Inc. (BLUE) are rallying, up over 17% in midday trading after positive results came in for its experimental anti-BCMA CAR (chimeric antigen receptor) T-cell product candidate bb2121.